- Home
- EOD vs GALT Comparison
EOD vs GALT Comparison
Compare EOD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EOD | GALT |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.4M | 232.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EOD | GALT |
|---|---|---|
| Price | $5.98 | $5.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 118.1K | ★ 431.4K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.73 | $0.73 |
| 52 Week High | $4.71 | $6.66 |
Technical Indicators
Market Signals| Indicator | EOD | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 68.59 | 48.04 |
| Support Level | $5.58 | $5.67 |
| Resistance Level | $5.89 | $6.32 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 100.00 | 25.00 |
Price Performance
Historical ComparisonAbout EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.